PharmaMax Pharmaceuticals specializes in the research and industrialization of innovative drugs for respiratory and psychiatric diseases. [Photo/WeChat account: weigg6666]
The Amisulpride Oral Solution independently developed by PharmaMax Pharmaceuticals, located in China Medical City, Taizhou, Jiangsu province, has been approved by the National Medical Products Administration for the Chinese market.
"The medicine is a specialized treatment for schizophrenia. The launch marks a further expansion of our company's psychiatric drug matrix," said Chu Shuping, deputy president of the company.
The Amisulpride Oral Solution product. [Photo/WeChat account: weigg6666]
The company has launched five psychotropic generic drugs and plays a leading role in China's psychotropic drug development track.
It has been laying down pipelines to tackle respiratory diseases and mental illnesses since 2015. A decade ago, the research and development of psychiatric drugs was still a niche field, and PharmaMax Pharmaceuticals was one of the few domestic companies to focus on this field.
"In recent years, our company has steadily developed at a rate of two to three new products launched each year, allowing us to establish a foothold despite fierce market competition," added Chu.
Internationalization is the next goal for the company, according to Jiang Zhijun, its chairman and president. Jiang said multiple innovative drug products are in the preclinical application and clinical stages, with the goal being to sell them globally through diversified cooperation models.